Abstract | OBJECTIVE: DESIGN AND SETTING: Open-label study conducted at 15 primary care clinics. PATIENTS: RESULTS: Eighty-nine (62%) of 143 patients had previous exposure to triptans, with lack of prescribing (55%) as the primary reason for not continuing their use as first-line therapy. Medications used for first-line therapy included simple analgesics (59%), combination products (46%), and narcotics (13%). After treating 3 migraines with naratriptan, satisfaction with migraine therapy increased from 47% to 75%. Sixty-three percent of patients preferred naratriptan therapy over their previous nontriptan therapy, 27% preferred their previous therapy, and 10% had no preference. The main reasons for preference for naratriptan therapy were "relieves pain effectively" (86%) and "restores ability to function/perform task" (81%). CONCLUSION:
|
Authors | C Powers, S Szeto, D Pangtay, T Bort, M Cervi, R Cady |
Journal | Archives of family medicine
(Arch Fam Med)
Vol. 9
Issue 8
Pg. 753-8
(Aug 2000)
ISSN: 1063-3987 [Print] United States |
PMID | 10927717
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indoles
- Piperidines
- Serotonin Receptor Agonists
- Tryptamines
- Vasoconstrictor Agents
- naratriptan
|
Topics |
- Adult
- Aged
- Female
- Humans
- Indoles
(therapeutic use)
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Patient Satisfaction
(statistics & numerical data)
- Piperidines
(therapeutic use)
- Serotonin Receptor Agonists
(therapeutic use)
- Treatment Outcome
- Tryptamines
- Vasoconstrictor Agents
(therapeutic use)
|